A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations

Transplantation

Volumn 62, Issue 11, 1996, Pages 1565-1570

  Hourmant, Maryvonne ^a   Bedrossian, Jeanine ^b   Durand, Dominique ^c   Lebranchu, Yvon ^d   Renoult, Edith ^e   Caudrelier, Pierre ^f   Buffet, Renaud ^f   Soulillou, Jean Paul ^a  

^a HÔTEL DIEU   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d CHU BRETONNEAU   (France)

^e CHU NANCY BRABOIS   (France)

^f Pasteur Merieux Serums et Vaccins   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1 ANTIBODY; MONOCLONAL ANTIBODY; ODULIMOMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MALE; MIDDLE AGED; RABBITS; URINARY TRACT INFECTIONS;

EID: 0030466367     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612150-00006     Document Type: Article

References (39)

1. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46: 540.
2. Goldstein G, Schindler J, Tsai H, et al. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplant. N Engl J Med 1985; 313: 337.
3. Soulillou JP, Cantarovich D, Le Mauff B, et al. Randomized trial of an anti-interleukin 2 receptor monoclonal antibody (33B3.1) versus rabbit antithymocyte globulin (ATG) in prophylaxis of early rejection in human renal transplantation. N Engl J Med 1990; 322: 1175.
4. Reinke P, Kern F, Fietze E, et al. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients. CD4+ T cells play an essential role in the rejection proccess. Transplant Proc 1995; 27: 859.
5. Springer TA. Adhesion receptors in the immune system. Nature 1990; 346: 425.
6. Pals ST, Otter AD, Miedema F. Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. J Immunol 1988; 140: 1851.
7. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990; 75: 1037.
8. Marlin SD, Springer TA. Purified intercellular adhesion molecule-1 is a ligand for LFA1. Cell 1987; 51: 813.
9. Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA1 homologous to ICAM-1. Nature 1989; 339: 61.
10. De Fougerolles AR, Springer TA. Intercellular adhesion molecule 3, a third adhesion counter-receptor for LFA1 molecule on resting lymphocytes. J Exp Med 1992; 175: 185.
11. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA1. Nature 1989; 341: 619.
12. Van Kooyk Y, Van de Wiel P, Van Kemenade P, Weder P, Kuijpers TW, Figdor CG. Enhancement of LFA1 mediated cell adhesion by triggering through CD2 or CD3 on T lymphocytes. Nature 1989; 342: 811.
13. Dustin ML, Spinger TA. LFA1 interaction with ICAM1 is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J Cell Biol 1988; 107: 321.
14. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by TNF and interferon gamma. Tissue distribution, biochemistry and function of ICAM1. J Immunol 1986; 137: 245.
15. Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA1 ligand ICAM1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144: 4579.
16. Geissler G, Gaggl S, Most J, Greil R, Herold M, Dierich M. A monoclonal antibody directed against the human ICAM1 modulates the release of tumor necrosis factor alpha, interferon gamma and interleukine 1. Eur J Immunol 1990; 20: 259.
17. Dantal J, Soulillou JP. Use of monoclonal antibodies in human transplantation. Curr Opin Immunol 1991; 3: 740.
18. Haugh CE, Colvin RB, Delmonico FL, et al. A phase I trial of immunosuppression with anti-ICAM1 (CD54) in renal allograft recipients. Transplantation 1994; 55: 766.
19. Stoppa AM, Maraninchi D, Biaise D, et al. Anti-LFA1 monoclonal antibody (25-3) for treatment of steroid-resistant grade III-IV graft versus host disease. Transpl Int 1991; 4: 3.
20. Fisher A, Griscelli C, Blanche S, et al. Prevention of graft failure by an anti-LFA1 monoclonal antibody in HLA-mismatched bone marrow transplantation. Lancet 1986; 2: 1058.
21. Le Mauff B, Hourmant M, Rougier JP, et al. Effect of anti-LFA1 monoclonal antibodies in acute rejection in human kidney transplantation. Transplantation 1991; 52: 291.
22. Hourmant M, Le Mauff B, Le Meur Y, et al. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation. A pilot study. Transplantation 1994; 58: 377.
23. Le Mauff B, Le Meur Y, Hourmant M, et al. A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients. Kidney Int 1996; 49 (suppl 53): 44.
24. Olive D, Charmot D, Dubreuil P. Human lymphocyte functional antigens. In: Feldmann M, ed. Human T cell clones. A new approach to immune regulation. Clifton, NJ: Humana Press, 1986: 173.
25. Champe M, McIntyre W, Berman PW. Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a. J Biol Chem 1995; 270: 1388.
26. Solez K, Benediktsson H, Burdick JF, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
27. Fuggle SV, Sanderson JB, Gray DWR, Richardson A, Morris PJ. Variation in expression of endothelial adhesion molecules in pre-transplant and transplanted kidneys. Correlations with intra-graft events. Transplantation 1993; 55: 117.
28. Bonnefoy-Bérard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal anti-lymphocyte and anti-thymocyte globulins. Transplantation 1991; 5: 669.
29. Galea P, Lebranchu Y, Thibault G, Bardos P. Interleukine 4 and tumor necrosis factor a induce different adhesion pathways in endothelial cells for the binding of peripheral blood lymphocytes. Scand J Immunol 1992; 36: 575.
30. Brockmeyer C, Ulbrecht M, Schendel DJ, et al. Distribution of cell adhesion molecules (ICAM1, VCAM1, ELAM1) in renal tissue during allograft rejection. Transplantation 1993; 55: 610.
31. Wellicome SM, Thornhill MH, Pitzalis C, et al. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by TNF, IL1 or LPS. J Immunol 1990; 144: 2558.
32. McCord JM. Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med 1985; 312: 159.
33. Linas SL, Shanley PF, Whittenburg D, Berger E, Repine JE. Neutrophils accentuate ischemia-reperfusion injury in the isolated perfused kidney. Am J Physiol 1988; 255: F728.
34. Yoshida N, Granger D, Anderson D, Rothlein R, Lane C, Kvietys P. Anoxia/reoxygenation induce neutrophil adherence to cultured endothelial cells. Am J Physiol 1992; 262: H1891.
35. Kelly KJ, Williams WW, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994; 91: 812.
36. Peters TG, Shaver TR, Ames JE, Santiago-Delpin EA, Jones KW, Blanton JW. Cold ischemia and outcome in 17,937 cadaveric kidney transplants. Transplantation 1995; 59: 191.
37. Isobe M, Yagita H, Okumura K, Ihara A Specific acceptance of cardiac allograft after treatment with antibodies to ICAM1 and LFA1. Science 1992; 255: 1125.
38. Nishikawa K, Guo YJ, Miyasaka M, et al. Antibodies to ICAM1/LFA1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 1993; 177: 667.
39. Connolly MK, Kitchens EA, Chan B, Jardieu P, Wofsy D. Treatment of murine lupus with monoclonal antibodies to LFA1: dose-dependent inhibition of autoantibody production and blockade of the immune response to therapy. Clin Immunol Immunopathol 1994; 72: 198.